Literature DB >> 9485042

Human papillomavirus 16 E6 variants are more prevalent in invasive cervical carcinoma than the prototype.

I Zehbe1, E Wilander, H Delius, M Tommasino.   

Abstract

High-risk human papillomavirus (HPV) is a known risk factor in the etiology of cervical intraepithelial neoplasia (CIN) I-III and invasive cervical carcinoma (ICC). The most severe preinvasive lesion is CIN III, and it is still not entirely understood why some cases progress to invasion, whereas others do not. Our hypothesis that this could be predicted by intratype variation of the immortalizing and transforming early proteins E6 and E7 was tested. Because HPV16 is frequently detected in cervical neoplastic lesions, 25 CIN III and 17 ICC cases from Swedish women, all positive for this genotype, were selected to investigate the E6 and E7 genes for mutations. PCR-amplified products were sequenced by the fluorescent dideoxy termination method. ICC harbored almost exclusively HPV16 E6 variants (94%) and rarely harbored the prototype (6%), whereas CIN III demonstrated a more uniform distribution of variants (56%) and prototype (44%; P = 0.013). All variants contained variations that were identified in areas likely to be important for protein-protein interaction with p53 or in areas of immunological significance. The most frequent E6 variation was seen at residue 83. This polymorphism was detected alone or in combination with others in 88% of ICC and 44% of CIN III cases. E7 variations were extremely rare and were only detected together with E6 variations in 4% of CIN III and in 6% of ICC cases, suggesting that the HPV16 E7 but not the HPV16 E6 oncoprotein is highly conserved in vivo. This indicates that HPV16 E6 variants, specifically those containing the substitution at residue 83, may be more oncogenic than the prototype and thus carry a higher risk for the development of invasive cervical disease. This may be due to subtle differences in the type of transformation produced or to evasion of host immune defenses. These results might have implications for future in vitro studies, diagnostics, treatment, and vaccine design.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9485042

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  58 in total

1.  Development of a sensitive and specific assay combining multiplex PCR and DNA microarray primer extension to detect high-risk mucosal human papillomavirus types.

Authors:  Tarik Gheit; Stefano Landi; Federica Gemignani; Peter J F Snijders; Salvatore Vaccarella; Silvia Franceschi; Federico Canzian; Massimo Tommasino
Journal:  J Clin Microbiol       Date:  2006-06       Impact factor: 5.948

2.  Cervical keratinocytes containing stably replicating extrachromosomal HPV-16 are refractory to transformation by oncogenic H-Ras.

Authors:  Kristi L Berger; Felicia Barriga; Michael J Lace; Lubomir P Turek; Gideon J Zamba; Frederick E Domann; John H Lee; Aloysius J Klingelhutz
Journal:  Virology       Date:  2006-08-30       Impact factor: 3.616

3.  Association of HPV16 E6 variants with diagnostic severity in cervical cytology samples of 354 women in a US population.

Authors:  Rosemary E Zuna; William E Moore; Rebecca P Shanesmith; S Terence Dunn; Sophia S Wang; Mark Schiffman; Gregory L Blakey; Travis Teel
Journal:  Int J Cancer       Date:  2009-12-01       Impact factor: 7.396

4.  Amino acid residues in the carboxy-terminal region of cottontail rabbit papillomavirus E6 influence spontaneous regression of cutaneous papillomas.

Authors:  Jiafen Hu; Nancy M Cladel; Martin D Pickel; Neil D Christensen
Journal:  J Virol       Date:  2002-12       Impact factor: 5.103

5.  Longitudinal study of patients after surgical treatment for cervical lesions: detection of HPV DNA and prevalence of HPV-specific antibodies.

Authors:  R Tachezy; I Mikysková; V Ludvíková; L Rob; T Kucera; V Slavík; A Beková; H Robová; M Pluta; E Hamsíková
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2006-08       Impact factor: 3.267

6.  Human papillomavirus in upper digestive tract tumors from three countries.

Authors:  Andres Castillo; Chihaya Koriyama; Michiyo Higashi; Muhammad Anwar; Mulazim Hussain Bukhari; Edwin Carrascal; Lida Mancilla; Hiroshi Okumura; Masataka Matsumoto; Kazumasa Sugihara; Shoji Natsugoe; Yoshito Eizuru; Suminori Akiba
Journal:  World J Gastroenterol       Date:  2011-12-28       Impact factor: 5.742

7.  Human papillomavirus 16 E6 variants differ in their dysregulation of human keratinocyte differentiation and apoptosis.

Authors:  Ingeborg Zehbe; Christina Richard; Correne A DeCarlo; Anny Shai; Paul F Lambert; Hava Lichtig; Massimo Tommasino; Levana Sherman
Journal:  Virology       Date:  2008-11-04       Impact factor: 3.616

8.  Denaturing high-performance liquid chromatography for detecting and typing genital human papillomavirus.

Authors:  Jianduan Li; Daniela S Gerhard; Zhengyan Zhang; Phyllis C Huettner; Jason Wright; Loan Nguyen; Danielle Lu; Janet S Rader
Journal:  J Clin Microbiol       Date:  2003-12       Impact factor: 5.948

9.  Human papillomavirus type 16 E6 amino acid 83 variants enhance E6-mediated MAPK signaling and differentially regulate tumorigenesis by notch signaling and oncogenic Ras.

Authors:  Oishee Chakrabarti; Karthikeyan Veeraraghavalu; Vinay Tergaonkar; Yun Liu; Elliot J Androphy; Margaret A Stanley; Sudhir Krishna
Journal:  J Virol       Date:  2004-06       Impact factor: 5.103

10.  Guidelines of the Italian Society for Virology on HPV testing and vaccination for cervical cancer prevention.

Authors:  Luisa Barzon; Colomba Giorgi; Franco M Buonaguro; Giorgio Palù
Journal:  Infect Agent Cancer       Date:  2008-12-16       Impact factor: 2.965

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.